Table 3.
The mean values of chosen parameters of MM patients before and after treatment
| Cytokine | No. of patients | |||
|---|---|---|---|---|
| New diagnosed patients, N = 50 | Patients after treatment | |||
| After the treatment, N = 50 | With PR + VGPR + CR, N = 34 | With SD, N = 16 | ||
| BAFF [pg/ml] | 904.63 ± 439.8 | 721.04 ± 82.1* | 511.21 ± 221.3 | 982.2 ± 422.02** |
| APRIL [ng/ml] | 2.69 ± 0.4 | 1.54 ± 1.01* | 1.12 ± 0.32 | 2.59 ± 1.33** |
| TNF [pg/ml] | 20.58 ± 8.2 | 15.11 ± 4.29* | 10.37 ± 3.1 | 18.56 ± 11.36** |
| IL-6 [pg/ml] | 10.99 ± 9.0 | 6.12 ± 3.78.1* | 4.93 ± 1.07 | 12.6 ± 3.19** |
| VEGF [pg/ml] | 240.91 ± 121.0 | 176.03 ± 56.09* | 134.07 ± 54.16 | 245.44 ± 43.45** |
| sVEGFR2 [pg/ml] | 6,990.2 ± 2,704.5 | 4,359.4 ± 1,865.4* | 3,942.3 ± 1,920.1 | 5,129.8 ± 3,221.9** |
| VEGF expression | 26.09 ± 14.8 | 23.12 ± 11.3 | 22.5 ± 10.4 | 24.01 ± 12.4 |
| TNF expression | 11.62 ± 7.5 | 9.31 ± 5.32 | 8.76 ± 4.89 | 9.56 ± 5.49 |
| MVD | 19.74 ± 6.6 | 11.65 ± 4.30 | 9.65 ± 3.11 | 13.5 ± 4.72** |
| Syndecan-1 (CD138) expression | 73.12 ± 22.9 | 28.12 ± 16.88* | 16.22 ± 11.3 | 32.32 ± 56.1** |
The values are presented as mean ± SD
MM multiple myeloma, ISS International Staging System, BAFF B cell activating factors, APRIL a proliferation-inducing ligand, TNF tumour necrosis factor, IL-6 interleukin 6, VEGF vascular endothelial growth factor, sVEGFR2 soluble vascular endothelial growth factor receptor, MVD microvascular density
*p < 0.05 between before and after treatments of MM patients; **p < 0.05 between patients with response and stable disease